Antihistamines prescribed off-label among paediatric patients at a tertiary care hospital setting in Malaysia
Background Antihistamines are widely prescribed to children but should be used with caution in young children. Objective To determine the paediatric prescribing pattern of antihistamines with a focus on the off-label prescribing and factors that influence such prescribing. Setting Paediatric wards of a tertiary care hospital setting in Malaysia. Methods The pharmacy-based computer system and medical records were used to collect the required data. Labelling status of each antihistamine was determined based on the information provided in the product leaflets. Main outcome measure Antihistamines prescribed off-label and factors associated with such prescribing. Results Of the 176 hospitalised children aged <18 years prescribed with an antihistamine in the year 2012, 60.8 % received it in an off-label manner. Of 292 antihistamine prescription items, 55.5 % were prescribed off-label. Loratadine (35.3 %) was the most frequently prescribed antihistamine and chlorpheniramine maleate (34.0 %) was the most common antihistamine prescribed off-label. The main reason for the off-label prescribing of antihistamines was prescribing at higher than the recommended dose (30.2 %). Binary logistic regression showed that children aged <2 years (OR 12.65; 95 % CI 2.87–55.67) and the number of medications received (OR 1.14; 95 % CI 1.00–1.29) were significant predictors for the off-label prescribing of antihistamines. Conclusion Prescribing antihistamines for children in an off-label manner was prevalent at the studied locations and warrants further investigation on the consequences of such prescribing.
KeywordsAntihistamines Children Malaysia Off-label Paediatric wards
Special thanks to the pharmacy staff at the UKMMC for providing access to the computerised dispensing database of the pharmacy. The authors would also like to thank the staff at hospital medical records department for their help in retrieving the medical records.
No funding was received for this study.
Conflicts of interest
There are no conflicts of interest to declare.
- 2.Cuvillo AD, Sastre J, Montoro J, Jáuregui I, Ferrer M, Dávila I, et al. Use of antihistamines in pediatrics. J Investig Allergol Clin Immunol. 2007;2:28–40.Google Scholar
- 3.Chlorpheniramine [package insert]. Selangor, Malaysia: Pharmaniaga Manufacturing Bhd.Google Scholar
- 4.Desloratadine 0.5 mg/ml Oral Solution, Summary of Product Characteristics [cited 20 Jun 2016]. https://www.medicines.org.uk/emc/medicine/31670.
- 5.FDA Public Health Advisory: FDA recommends that over-the-counter (OTC) cough and cold products not to be used for infants and children under 2 years of age. United States: Food and Drug Administration 2008 [cited 20 Jun 2016]. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm051137.htm.
- 6.Drug Control Authority. Newsletter of the drug control authority, Malaysia. National Pharmaceutical Control Bureau: Ministry of Health Malaysia. 2009;45:1–12.Google Scholar
- 12.Turner S, Nunn A, Choonara I. Unlicensed drug use in children in the UK. Paediatr Perinat Drug Ther. 1997;1:52–5.Google Scholar
- 29.Statistik Hospital, Hospital Canselor Tuanku Muhriz 2011–2015 [cited 20 Jun 2016]. http://www.ppukm.ukm.my/jmk/wp-content/uploads/2016/02/statistikHospital.pdf.
- 30.Drug Formulary. 5th ed., 2010; Pharmacy Department, Universiti Kebangsaan Malaysia Medical Centre.Google Scholar
- 34.ICH Expert Working Group. International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH harmonised tripartite guidelines, clinical investigation of medicinal products in the pediatric population (E11); 2000 [cited 20 Jun 2016]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step4/E11_Guideline.pdf.
- 43.Ramakrihnan K, Sparks RA, Berryhill WE. Diagnosis and treatment of otitis media. Am Fam Physician. 2007;76:1650–8.Google Scholar
- 47.Aerius® Tablets, brand of desloratadine [package insert]. Whitehouse Station, NJ: Merck Sahrp & Dohme Co.; 2012.Google Scholar
- 48.Master Index of Medical Specialties (MIMS) Malaysia [cited 21 Jun 2016]. www.mims.com.
- 49.Promethazine [package insert]. Selangor, Malaysia: CCM Pharmaceuticals Sdn. Bhd.Google Scholar
- 50.Telfast® D, Fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg [package insert]. Compiegne, France. Sanofi Winthrop Industrie; 2014.Google Scholar